Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin
2. Ly 333328
3. Ly-333328
4. Ly333328
5. Orbactiv
1. 171099-57-3
2. Ly333328
3. Oritavancin [inn]
4. Ly-333328
5. Chlorobiphenyl-chloroeremomycin
6. Pug62frz2e
7. Chebi:82699
8. Kimyrsa
9. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabinohexopyranosyl)-n3''-(p-(p-chlorophenyl)benzyl)vancomycin
10. Unii-pug62frz2e
11. Chembl1688530
12. Orita-vancin
13. Ly 333328
14. C12034
15. Oritavancin [mi]
16. Oritavancin [vandf]
17. Oritavancin [mart.]
18. Oritavancin [who-dd]
19. Oritavancin; Ly-333328
20. Schembl9947049
21. Gtpl10877
22. Dtxsid20897570
23. Bdbm513037
24. Ex-a2372
25. Db04911
26. Ncgc00485478-01
27. Ncgc00485478-02
28. Q7102878
29. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n(sup 3)''-(p-(p-chlorophenyl)benzyl)vancomycin
30. (4''r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin
31. (4'r)-22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-arabino-hexopyranosyl)-n(sup 3)' -(p-(p-chlorophenyl)benzyl)vancomycin
32. Vancomycin, 22-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-l-arabino-hexopyranosyl)-n3''-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)-, (4''r)-
Molecular Weight | 1793.1 g/mol |
---|---|
Molecular Formula | C86H97Cl3N10O26 |
XLogP3 | 1.5 |
Hydrogen Bond Donor Count | 20 |
Hydrogen Bond Acceptor Count | 29 |
Rotatable Bond Count | 19 |
Exact Mass | 1790.564106 g/mol |
Monoisotopic Mass | 1790.564106 g/mol |
Topological Polar Surface Area | 561 Ų |
Heavy Atom Count | 125 |
Formal Charge | 0 |
Complexity | 3700 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 22 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Oritavancin is indicated for the treatment of adult patients with acute bacterial skin and skin structure (including subcutaneous) infection. It is used for confirmed/suspected infections with designated and susceptible gram-positive organisms. There are two preparations of oritavancin; the 400 mg dose that is administered over 3 hours, and the 1200 mg dose administered over 1 hour. Both are indicated for susceptible gram-positive skin and skin structure infections in adults. As antimicrobial susceptibility patterns are geographically distinct, local antibiograms should be consulted to ensure adequate coverage of relevant pathogens prior to use.
FDA Label
Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults (see sections 4. 4 and 5. 1).
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Oritavancin interferes with bacterial cell wall synthesis and integrity, treating susceptible skin and subcutaneous tissue infections with gram-positive bacteria. This drug is known to artifically increase INR and aPTT, interfering with coagulation testing. Cases of infusion reactions have also been reported.
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
J01XA05
J - Antiinfectives for systemic use
J01 - Antibacterials for systemic use
J01X - Other antibacterials
J01XA - Glycopeptide antibacterials
J01XA05 - Oritavancin
Absorption
Pharmacokinetic analysis of oritavancin revealed a Cmax of 138 and g/mL and an AUC0- of 2800 gh/mL. The AUC0-t in a study of healthy volunteers after an 800 mg dose 1,1111 gh/mL. was also be Another pharmacokinetic study reported a Cmax of 4.7-7.6 micrograms/mL, generally achieved within 24 hours of administration.
Route of Elimination
Oritavancin is excreted as unchanged drug in both the urine and feces. Less than 5% has been recovered in the urine, and 1% has been recovered in the feces.
Volume of Distribution
The volume of distribution of oritavancin is estimated at 87.6 L, suggesting extensive tissue distribution.
Clearance
The clearance of oritavancin is approximately 0.445 L/h. One study revealed a renal clearance of 0.457 mL/min.
In vitro studies on human hepatocytes suggest that oritavancin is not metabolized, and is excreted unchanged.
The average terminal half-life of oritavancin is about 245 hours. A pharmacokinetic study revealed a terminal half-life ranging from 135.8-273.8 hours.
The cell wall is vital for the survival and replication of bacteria, making it a primary target for antibiotic therapy. Oritavancin works against susceptible gram-positive organisms via three separate mechanisms. Firstly, it binds to the stem peptide of peptidoglycan precursors, inhibiting transglycosylation (polymerization). This process normally occurs during cell wall synthesis. Secondly, oritavancin inhibits crosslinking during bacterial cell wall biosynthesis via binding to cell wall pentaglycyl peptide bridging segments. Finally, this drug also acts by disrupting the bacterial cell membrane, interfering with its integrity, which eventually leads to cell death by various mechanisms.
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ABOUT THIS PAGE
A Oritavancin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Oritavancin, including repackagers and relabelers. The FDA regulates Oritavancin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Oritavancin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Oritavancin manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Oritavancin supplier is an individual or a company that provides Oritavancin active pharmaceutical ingredient (API) or Oritavancin finished formulations upon request. The Oritavancin suppliers may include Oritavancin API manufacturers, exporters, distributors and traders.
click here to find a list of Oritavancin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Oritavancin as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Oritavancin API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Oritavancin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Oritavancin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Oritavancin NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Oritavancin suppliers with NDC on PharmaCompass.
Oritavancin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Oritavancin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Oritavancin GMP manufacturer or Oritavancin GMP API supplier for your needs.
A Oritavancin CoA (Certificate of Analysis) is a formal document that attests to Oritavancin's compliance with Oritavancin specifications and serves as a tool for batch-level quality control.
Oritavancin CoA mostly includes findings from lab analyses of a specific batch. For each Oritavancin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Oritavancin may be tested according to a variety of international standards, such as European Pharmacopoeia (Oritavancin EP), Oritavancin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Oritavancin USP).
LOOKING FOR A SUPPLIER?